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Summary
Longevity in mammals is influenced by sex, and lifespan extension in response to
anti-aging interventions is often sex-specific, although the mechanisms underlying
these sexual dimorphisms are largely unknown. Treatment of mice with 17-a
estradiol (17aE2) results in sex-specific lifespan extension, with an increase in
median survival in males of 19% and no survival effect in females. Given the links
between lifespan extension and metabolism, we performed untargeted metabolo-
mics analysis of liver, skeletal muscle and plasma from male and female mice trea-
ted with 17aE2 for eight months. We find that 17aE2 generates distinct sex-
specific changes in the metabolomic profile of liver and plasma. In males, 17aE2
treatment raised the abundance of several amino acids in the liver, and this was
further associated with elevations in metabolites involved in urea cycling, suggest-
ing altered amino acid metabolism. In females, amino acids and urea cycling
metabolites were unaffected by 17aE2. 17aE2 also results in male-specific eleva-
tions in a second estrogenic steroid—estriol-3-sulfate—suggesting different meta-
bolism of this drug in males and females. To understand the underlying endocrine
causes for these sexual dimorphisms, we castrated males and ovariectomized
females prior to 17aE2 treatment, and found that virtually all the male-specific
metabolite responses to 17aE2 are inhibited or reduced by male castration. These
results suggest novel metabolic pathways linked to male-specific lifespan extension
and show that the male-specific metabolomic response to 17aE2 depends on the
production of testicular hormones in adult life.
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1 | INTRODUCTION
Males and females in most species differ in their aging rates and
lifespan. In humans, sexual dimorphism is observed in the onset,*These authors contributed equally to this work.
†Co-Senior Author.
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severity, and/or frequency of age-associated metabolic dysfunction,
frailty, cancers, and some forms of neurological disease, with part of
this disparity linked to the underlying effects of sex-specific gonadal
hormone production across life (Legato, 2010). Male testicular pro-
duction of testosterone has been postulated to reduce male lifespan
compared to females (Brooks & Garratt, 2017), and castration has
been associated with longer lifespan in several mammal species,
including humans (Hamilton & Mestler, 1969; Min, Lee & Park,
2012), primates (Kessler et al., 2016), sheep (Jewell, 1997), and
rodents (Asdell, Doornenbal, Joshi & Sperling, 1967; Muehlbock,
1959), suggesting a potential common and conserved biological
mechanism. At the same time, estrogen production has been linked
to female-specific health benefits (Regan & Partridge, 2013), with
ovariectomy reported to reduce female rodent lifespan in some
instances (Benedusi et al., 2015; Mason, Cargill, Anderson & Carey,
2009).
17-b estradiol is the dominant female sex hormone produced
from the ovaries in adult life. Female-specific production of 17-b
estradiol contributes to sex differences in metabolism, supported
by the observation that circulating 17-b estradiol production decli-
nes during menopause, a fall associated with lower glucose home-
ostasis and elevated visceral adiposity (Mauvais-Jarvis, 2015).
However, other estrogens, and estrogenic actions outside of the
classical ER receptors, are increasingly recognized to have potential
health and anti-aging benefits, which may mimic or operate outside
of the effects of 17-b estradiol on its best-characterized receptors.
This study focuses on a stereoisomer of 17-b estradiol, 17-a estra-
diol (17aE2). Due to the stereochemistry of the carbon atom 17,
17aE2 has a much weaker binding affinity to the classical estrogen
receptors, and in some situations has a greater binding affinity for
other estrogen receptors, including the brain ER receptor ER-X
(Toran-Allerand, Tinnikov, Singh & Nethrapalli, 2005; Toran-Allerand
et al., 2002). 17aE2 has a range of bioactive properties, including
inflammatory and antioxidant effects (Moos, Dykens, Nohynek,
Rubinchik & Howell, 2009), and an ability to inhibit the activity of
5-alpha reductase enzymes (Schriefers, Wright, Rozman & Hevert,
1991), which convert testosterone to dihydrotestosterone, a more
potent activator of the androgen receptor. Treatment of male mice
with 17aE2 has been shown to extend median lifespan by 19%
(Strong et al., 2016), ameliorate age-associated metabolic and
inflammatory dysfunction (Stout et al., 2016), and improve male
glucose tolerance across much of adult life (Garratt, Bower, Garcia
& Miller, 2017).
The effects of 17aE2 on lifespan and metabolic health are
strongly sex-specific. Females accrue no detectable metabolic benefit
of 17aE2 treatment, and no life extension has been observed at the
two tested concentrations to date (Harrison et al., 2014; Strong
et al., 2016). We have previously observed that male-specific
increases in glucose tolerance and hepatic mTORC2 signaling with
17aE2 treatment are inhibited in males that are castrated in adult-
hood, prior to treatment onset (Garratt et al., 2017). Ovariectomy
(OVX) of females prior to treatment with 17aE2 had little effect on
these physiological responses, with OVX females showing no
improvement in glucose tolerance after 17aE2 treatment. The modu-
lation of sex-specific responsiveness to 17aE2 with male castration,
but not female ovariectomy, suggests that the sex-specificity in
responsiveness to 17aE2, at least in relation to glucose tolerance, is
caused by an interaction with male gonadal hormones, such as pro-
duction of testosterone.
Untargeted metabolomics provides a powerful approach to
understand the underlying metabolic responses that occur after
drug treatment or other manipulations. Association of metabolite
changes with particular pathways can reveal the biochemical and
metabolic processes consistently altered by an intervention, and
molecules that are identified as most strongly affected by an inter-
vention are candidates for a role in the intervention response. In
this study, we used untargeted metabolomic analysis of liver tissue
to identify metabolite responses that occur in mice treated with
17aE2 at the concentration previously shown to extend male but
not female lifespan. The liver is a key tissue involved in regulation
of glucose, carbohydrate, and protein metabolism, with previous
research showing that the metabolite profile of the liver changes
in response to lifespan extending manipulations in line with
expected alterations in energy utilization (e.g., calorie restriction
(Green et al., 2017)). We focused our investigation on liver
metabolites that show a sex-specific response to 17aE2 and may
underlie the male-specific lifespan response. Comprehensive meta-
bolomics revealed previously unrecognized metabolite changes that
were male-specific in response to 17aE2 and were abrogated by
male castration. These studies suggest that sex-specific metabolite
responses to 17aE2 are modulated by testicular hormones and
provide new insight into the mechanisms of sexual dimorphism in
lifespan extension.
2 | RESULTS
2.1 | Untargeted assessment of sex-specific
metabolite responses to 17aE2
To uncover the metabolic underpinnings of sex-specific lifespan
extension with 17aE2, male and female mice were treated with
17aE2 for eight months starting at 4 months of age, after which liver
samples were subjected to comprehensive untargeted metabolomics
analysis of polar and nonpolar (lipid) metabolites. Liquid chromatog-
raphy–mass spectrometry (LC-MS)-based metabolomics detected
10,271 unique spectral features in liver. To identify metabolites that
show a change with treatment consistent with lifespan extension (al-
tered in males but not females), we ran two-way ANOVAs for each
metabolite, including sex, treatment, and an interaction between sex
and treatment as factors. We focused on the interaction as the sta-
tistical term of interest, and prioritized metabolites that were altered
in males but not females, as these changes were correlated with the
male-specific lifespan response.
Across the initial >10,000 spectral features, we identified six
metabolites that showed a significant sex by treatment interaction
after correction for multiple comparisons (FDR p < 0.05; Table 1).
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Four of these showed a change primarily in males but not
females, of which one was strongly reduced in livers of 17aE2-
treated males, while three were strongly increased in males. These
metabolites represent sex-specific signals that correlate with the
sex-specific lifespan response (and could be used to determine the
effects of gonadectomy on treatment responses, see below).
Chemical networking of the four prioritized metabolites revealed
two metabolites at m/z 367.1221 and m/z 365.1086 to be chemi-
cally related, with distinct clustering (Figure 1a). Manual inspection
of extracted ion chromatograms for both related peaks confirmed
a stronger elevation in males treated with 17aE2 than in females
(Figure 1b). Manual inspection of fragmentation MS/MS spectra
for the two unknown metabolites at m/z 367.1221 and m/z
365.1086 revealed them to be estriol-3-sulfate and 16-oxoestradiol
3-sulfate, respectively (Figure 1c). Estriol-3-sulfate and 16-oxoestra-
diol 3-sulfate are two estrogenic compounds of a similar chemical
structure and may be metabolized from 17aE2 via 16 alpha
hydroxylation (Longcope 1984). These results indicate that 17aE2
undergoes sex-specific metabolism in male mice to secondary
estrogenic products.
2.2 | Modulation of liver metabolome with 17aE2
treatment
To test whether 17aE2 results in coordinated changes in metabo-
lites associated with specific metabolic processes, a subset of
metabolites were identified from untargeted metabolomic analysis
of liver samples following treatment with 17aE2. Using pure stan-
dards, 148 metabolites were identified based on retention time,
accurate mass characteristics, and MS/MS fragmentation patterns.
Twenty-five of the 148 metabolites were significantly altered in
abundance in the livers of 17aE2-treated males compared to
untreated males (uncorrected for multiple comparisons), with the
vast majority of metabolites (24/25) found to increase (Table 2).
17aE2 was found to result in a similar (24) number of metabolite
changes in female livers (Table S1), although only three fatty acids
—eicosatrienoic acid, docosatrienoic acid, and behenic acid—in-
creased in the livers of both sexes with treatment. Approximately
50% of the metabolites significantly altered in abundance in
17aE2-treated females decrease in abundance compared to con-
trols.
TABLE 1 Metabolites showing a sex-specific response to 17aE2 treatment. Data are split into whether the metabolite was initially
untargeted or was identified by standard during analysis. M.Z. and retention time (RT, minutes) are shown for untargeted metabolites. Analysis
is then further split by whether the metabolite change is seen in females or males. p-values shown in Table 1 are uncorrected for multiple
comparisons
Metabolite
Treatment interaction (p-value two-Way
ANOVA) Effect of 17aE2 (p-value Student’s t test)
Sex (intact mice) Cast (male) OVX (female) Male Female Cast Male OVX Female
Sample size control 8 7 8 8
Sample size 17aE2 9 8 8 8
Untargeted metabolites
Male response M.Z. R.T.
MET01834 461.2 1.49 0.000014 0.0050 0.22 ↑ 0.000001 0.97 ↑ 0.0000 0.14
Estriol-3-sulfate 367.1 1.80 0.000017 0.0000 0.23 ↑ 0.000013 0.16 ↑ 0.0012 0.15
MET03323 437.0 2.75 0.000027 0.0000 0.005 ↓ 0.000006 0.82 0.39 0.0059
16-oxoestradiol 3-sulfate 365.1 1.78 0.000029 0.0060 0.16 ↑ 0.000007 0.12 ↑ 0.0008 0.13
Female response
MET03545 377.3 3.45 0.000001 0.31 0.0000 0.38 ↓ 0.0000 0.32 0.058
MET03666 459.3 3.45 0.000001 0.29 0.0000 0.77 ↓ 0.0000 0.33 0.057
Identified by standard
Male response
Phosphocholine 0.00074 0.23 0.51 ↑ 0.0010 0.13 0.37 0.79
4-imidazoleacetic acid 0.0012 0.02 0.14 ↑ 0.0017 0.29 ↑ 0.029 0.25
N-alpha acetyl_Lysine 0.0061 0.018 0.61 ↑ 0.0040 0.62 0.67 ↓ 0.048
n-alpha-acetyl-l-asparagine 0.00998 0.063 0.37 ↑ 0.024 0.18 0.78 0.57
Female response
Betaine 0.00077 0.062 0.065 0.13 ↓ 0.0019 0.27 ↓ 0.044
Changed in both
n-acetyl-dl-glutamic acid 0.0076 0.13 0.082 0.081 ↓ 0.016 0.58 0.91
l-serine 0.0083 0.038 0.19 0.056 0.072 0.61 0.085
Corticosterone 0.0084 0.0070 0.33 ↑ 0.039 0.067 0.089 0.59
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We conducted Quantitative Metabolomic Set Enrichment
Analysis to test whether 17aE2 leads to coordinated shifts in
metabolites associated with any particular metabolic process. This
analysis uses generalized linear models to estimate the associa-
tion between concentration profiles of different metabolites
linked to a particular metabolic process and can detect subtle
changes in coordinated sets of metabolites (Xia & Wishart, 2010).
We conducted this analysis separately for each sex, as we were
particularly interested in metabolites and metabolomic responses
that changed specifically in males, and thus are associated with
male-specific lifespan extension. Metabolite responses in each sex
were referenced against the “metabolite pathway database,”
which links groups of metabolites to 88 different pathways.
Metabolite pathway associations with 17aE2 treatment within
each sex are shown in Table S2. For males, 17aE2 treatment
leads to a significant shift in metabolites enriched in pathways
associated with “protein biosynthesis” and the “urea cycle.” By
contrast, for females, 17aE2 treatment leads to modulation of
metabolites associated with “betaine metabolism.” This mainly
reflects the effect of 17aE2 treatment in females reducing hep-
atic levels of betaine and dimethylglycine, and increasing S-ade-
nosylhomocysteine (Fig. S1).
In males, pathway enrichment for metabolites associated with
“protein biosynthesis” reflected the induction by 17aE2 of a male-
specific elevation in many amino acids, including alanine, arginine,
glutamine, ornithine, and valine (Figure 2). Metabolite enrichment for
the urea cycle reflected increases in both alanine and glutamate, and
direct urea cycle intermediates, including argininosuccinic acid, argi-
nine, and ornithine (Figure 3).
2.3 | Identified metabolites showing a sex-specific
response to 17aE2
We further assessed changes in individual known metabolites with
17aE2 treatment, again focusing on metabolites that change
specifically in males but not females, as indicated by a significant
two-way interaction between sex and treatment, and also showing
a nominally significant response to 17aE2 in males. Table 1 shows
those known metabolites that show a differential response to
17aE2 treatment according to sex; the associated p-values are
shown in the “Sex” column for intact mice. Most notable is the
male-specific increase in N-acetylated amino acids, lysine and
asparagine (Figure 4a,b). N-acetylated amino acids, including N-
acetyl lysine, are strongly correlated to urea cycle metabolite























































F IGURE 1 Identification of two metabolites that show a sex-specific response to 17aE2. (a) Chemical networking of unknown metabolites,
with nodes representing an individual metabolite MS/MS spectrum and edge thickness, indicating cosine similarity between metabolites. Area
within the red box is highlighted with red nodes representing two related metabolites at m/z 367.1221 and 365.1086 from among the four
prioritized metabolites. (b) Chromatograms for metabolites m/z 367.1221 and m/z 365.1086 in the four animal groups, with male control
group (blue), female control group (gray), male 17-a estradiol group (black), and female 17-a estradiol group (red). (c) MS/MS, structure, and
fragmentation markup for metabolites m/z 367.1221 and m/z 365.1086, identifying the metabolites as estriol 3-sulfate and 16-oxoestradiol 3-
sulfate, respectively
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concentrations in human red blood cells collected from old
(>80 years) humans (Chaleckis, Murakami, Takada, Kondoh &
Yanagida, 2016). While these are increased by 17aE2 in liver of
males they are unaffected in females (Figure 3). The metabolite
showing the most significant sex*17aE2 interaction within the
known metabolite dataset is phosphocholine (Sex*Treatment inter-
action: raw p-value <0.0007; Table 1; Figure 4c), which is
increased in males but unaffected in females, and can be produced
as a product of serine, glycine and threonine metabolism. Also of
interest, and potentially linked to protein metabolism, is the male-
specific increase in corticosterone, which in females decreases,
though not significantly (Figure 4E; Table 1). We have previously
shown that activation of the serum glucocorticoid receptor 1
(SGK1), a direct target of corticosterone, is also elevated sex-spe-
cifically in 17aE2-treated males (Garratt et al., 2017). The sex-spe-
cific metabolite that represents a change specifically in females is
betaine, which is decreased in 17aE2-treated females compared to
controls (Table 1; Fig. S1).
2.4 | Sex-specific metabolomic responses are
inhibited by male castration
To test whether the sex-specific metabolomic effects of 17aE2 are
generated by the underlying effects of male or female gonadal hor-
mones, we castrated male mice and ovariectomized female mice at
three months of age, that is, one month prior to administration of
17aE2, and tested whether this postpubertal gonadectomy altered
sex-specific metabolite responses to 17aE2. These animals were pro-
duced and evaluated in parallel with the intact (sham-operated) ani-
mals described above. All six of the metabolites showing a sex by
treatment interaction (i.e., those where FDR < 0.05) across the
untargeted dataset showed a response that was dependent on
gonadectomy. The four metabolites strongly altered in 17aE2-treated
male livers, which include estriol-3-sulfate and 16-oxoestradiol 3-sul-
fate, show a significantly diminished response to 17aE2 treatment in
castrated males (Figure 5), indicated by the interaction terms within
males for “Castration” in Table 1.
TABLE 2 Metabolites that are significantly affected by 17aE2 treatment in males. Arrows indicate direction of change with 17aE2
treatment. p-values are generated by a Student’s t test, with the exception of data for arginine, where a Mann–Whitney U test was used
because of the presence of several zero values. The comparable analysis for each metabolite is also shown for females, castrated males, and
OVX females. Sample sizes are shown in Table 1
ID
Male Female Castrated males OVX females
Change p value Change p value Change p value Change p value
Phosphocholine ↑ 0.001 0.130 0.368 0.789
4-Imidazoleacetic acid ↑ 0.002 0.291 ↑ 0.029 0.253
Docosahexaenoic Acid ↑ 0.003 0.491 0.827 0.919
Arginine ↑ 0.004 0.460 0.560 0.160
N alpha-acetyl-L-lysine ↑ 0.004 0.624 0.671 ↓ 0.048
Docosadienoic Acid ↑ 0.006 0.211 0.597 0.098
Allothreonine ↑ 0.006 0.708 0.747 0.977
Glutamine ↑ 0.006 0.128 0.212 0.124
Eicosatrienoic Acid ↑ 0.010 ↑ 0.035 0.535 ↑ 0.047
Ornithine ↑ 0.012 0.594 0.969 0.457
Adrenic Acid ↑ 0.013 0.744 0.575 0.131
Eicosadienoic Acid ↑ 0.015 0.118 0.746 0.202
Argininosuccinic acid ↑ 0.015 0.826 0.598 0.791
Alanine ↑ 0.016 0.093 0.945 0.025
D-Ribulose 5-phosphate ↑ 0.020 0.224 0.395 ↑ 0.778
Behenic Acid ↑ 0.024 ↑ 0.014 0.671 0.690
N-alpha-acetyl-L asparagine ↑ 0.024 0.175 0.785 0.569
Valine ↑ 0.027 0.772 0.923 0.790
Proline ↑ 0.029 0.211 0.559 0.346
Docosatrienoic Acid ↑ 0.032 ↑ 0.018 0.737 0.264
N-aceytl-DL-serine ↑ 0.037 0.273 ↑ 0.004 ↑ 0.021
Arachidonic Acid ↑ 0.037 0.666 0.885 0.901
Dethiobiotin ↑ 0.038 0.600 0.126 0.521
Corticosterone ↑ 0.039 0.067 0.089 0.591
Trans-4-hydroxyproline ↓ 0.049 0.455 0.442 0.921
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We also tested whether gonadectomy altered the effects of
17aE2 treatment on known metabolites associated with specific
metabolic pathways in either sex. Of the 25 known metabolites
altered by 17aE2 treatment in normal (sham)-treated males, only two
(4-imidazoleacetic acid and N-acetyl-DL-serine) were also signifi-
cantly changed, in the same direction, in castrated males treated
with 17aE2 (Table 2). For 4-imidazoleacetic acid the response in this
metabolite with 17aE2 was significantly diminished, as indicated by
the “castration” interaction in Table 1. When considering known
metabolite responses to 17aE2 in castrated males, enrichment analy-
sis failed to show a significant association in metabolite responses
with any particular biochemical pathway after correction for FDR,
and there was no evidence that amino acids or metabolites of the
urea cycle were affected by 17aE2 treatment in castrated males
(Table S3; Fig. S2). Thus, the male-specific elevations in metabolites
associated with protein biosynthesis and the urea cycle with 17aE2
treatment require male-specific production of gonadal hormones.
Ovariectomized females did not show significant enrichment for any
specific biochemical pathway after correction for FDR, although it is
notable that betaine metabolism, which is altered in sham females,
was also modulated in OVX females in the analysis before correction
for multiple comparisons by the FDR calculation, and this pathway
did produce FDR = 0.07 in the ovariectomized females (Table S3).
2.5 | Sex-specific metabolite responses in plasma
are also inhibited by castration
To test whether the testosterone dependence of male-specific
responses is an effect that is restricted to the liver, or represents a
more general sexual dimorphism in metabolomic response, we
assessed metabolomic responses to 17aE2 treatment in plasma. As
the strongest sex-specific responses in liver were observed for
bioactive lipids, we restricted our analysis to this sampling method.
We observed 13 metabolites that both showed a significant
sex*17aE2 interaction after correction for FDR and represented
responses where the metabolite changed significantly in intact males
but not females (thus correlating with the lifespan response). In each
case, the significant male response was not observed in castrated
males (Table S4), highlighting its dependence on male gonadal hor-
mones, just as in the analysis of male-specific liver metabolic
changes.
In addition to these initially unidentified metabolites in plasma,
our analysis identified 24 different free fatty acid species (Table 3).
Ten of these were significantly increased in the plasma of 17aE2-
treated males. Only two showed a shared effect in females. 17aE2-
treated female mice show a significant reduction in a different sub-
set of these lipids (Table 3). The effects of 17aE2 on plasma free
fatty acid abundance are greatly diminished by castration, with only
one of 24 fatty acids changing with treatment (Table 3), consistent
with the analysis of castration effects on liver metabolite profile.
2.6 | Changes in amino acid abundance with 17aE2
are not observed in skeletal muscle
Skeletal muscle is an additional important source of amino acids that
can move to the liver during catabolic periods. To test whether the
increase in amino acids in livers was correlated with changes in mus-
cle, we assessed whether amino acids levels were increased in
quadriceps samples collected at the same time point as livers. We
observed no changes in amino acids in response to 17aE2 (Fig. S3).
Furthermore, there was a general lack of metabolite responsiveness
in muscle to 17aE2, with enrichment analysis failing to show a coor-
dinated response for metabolites in any included pathway (Table S5).
3 | DISCUSSION
Our results document marked sex-specific metabolomic effects of
17aE2, a steroid that leads to substantial male-specific lifespan
extension (Strong et al., 2016), in addition to male-specific
F IGURE 2 Elevated hepatic amino acids in males treated with
17aE2. Enrichment analysis (Table S2) showed that metabolites
associated with protein biosynthesis were significantly enriched in
males treated with 17aE2. This reflects an increase in the abundance
of a range of amino acids, an effect that was observed in males but
not females. * = p < 0.05 calculated with a Student’s t test. N = 7–9
per treatment group, per sex. Error bars show mean  SEM for
standardized abundance values
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improvements in glucose tolerance (Garratt et al., 2017) and lowered
age-related inflammatory dysfunction (Stout et al., 2016). Although
17aE2 has no detectable lifespan effect in females, our data show
that it does produce changes in liver and plasma metabolite profiles
in this sex, changes that differ from those seen in males. In males,
17aE2 increases the abundance of a variety of amino acids and
metabolites involved in the production of urea in the liver. For
females, 17aE2 lowers the hepatic abundance of several metabolites
associated with betaine metabolism. As with all metabolomic studies,
the ability to detect a pathway response is dependent on the meth-
od’s coverage of related metabolites—there may be metabolomic
responses to 17aE2 that our methodological approach did not
detect. Nonetheless, our analysis reveals a clear, male-specific,
metabolite response to 17aE2 that is dependent on male gonadal
hormone production and could be linked to the health and metabolic
benefits of this treatment, although future experimental studies are
required to prove a causal link.
The increase in levels of amino acids in 17aE2-treated males sug-
gests that treated males show changes in aspects of protein metabo-
lism. Elevations of hepatic amino acid levels are also observed with
other lifespan extending manipulations in rodents, including calorie
restriction (CR) and treatment with acarbose (Gibbs, Brewer, Miya-
saki, Patki & Smith, 2017; Green et al., 2017). Acarbose extends
lifespan to a much greater degree in male than in female mice (Har-
rison et al., 2014), while CR works equally in both sexes (Simons,
Koch & Verhulst, 2013). A study of fibroblasts from multiple species
of rodents, birds, and primates also documented higher levels of 10
















































































F IGURE 3 Changes in metabolites associated with the urea cycle in livers of 17aE2-treated mice. Enrichment analysis showed that males
treated with 17aE2 show a significant enrichment in metabolites associated with the urea cycle, while these effects are not observed in
17aE2-treated females. * = p < 0.05, **p < 0.01 calculated with a Student’s t test. N = 7–9 per treatment group, per sex. Error bars show
mean  SEM, and individual data points show the intensity value for each individual
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F IGURE 4 Identified metabolites
showing a sex-specific response to 17aE2
treatment and a change in treated males,
and inhibition of these sex-specific
responses by male castration. Statistics are
shown in Table 1. * = p < 0.05, **p < 0.01
calculated with a Student’s t test. N = 7–9
per treatment group, per sex. Error bars
show mean  SEM for abundance values
of each metabolite
F IGURE 5 Metabolites showing a sex-
specific response to 17aE2 treatment in
intact animals. Figure shows the
metabolites that were subsequently
identified as estriol-3 sulfate (a) and 16-
oxoestradiol 3-sulfate (c). In each panel,
data are shown for 17aE2-treated intact
animals on the left and animals that had
gonads removed prior to treatment on the
right. N = 7–9 per group. Statistics are
shown in Table 1. Error bars show
mean  SEM
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(Ma et al., 2016). Thus, elevated amino acid abundance is a consis-
tent feature of mammalian life extension.
In our study, we also observe elevations in metabolites related to
the urea cycle with 17aE2, which are produced as a consequence of
amino acid catabolism. This could suggest that 17aE2 promotes the
utilization of amino acids as a metabolic fuel, potentially in an amino
acid specific way, although this hypothesis requires experimental val-
idation. In our study, we observe significant elevations in glucogenic
amino acids (e.g., alanine, arginine, glutamine, and valine), which
could suggest that amino acid metabolism provides energy via con-
version to glucose. It is notable that valine was significantly
increased with 17aE2 treatment while the other branched-chain
amino acids (BCAA, leucine and isoleucine) were not significantly
altered. While initiation of catabolism of these three BCAAs occurs
via the same enzyme (branched-chain keto acid dehydrogenase), the
subsequent steps are mediated by different enzymes. Furthermore,
valine is exclusively glucogenic, while isoleucine is both keto- and
glucogenic and leucine is exclusively ketogenic. Thus, although the
concentration of these amino acids is often highly correlated, their
metabolism can differ in a state and tissue-specific manner (Brosnan
& Brosnan 2006). Indeed, while long lifespan has been associated
with elevations in selected amino acids in previous studies, the
published work has sometimes documented a lack of concordance in
BCAA responses. With CR, for example, elevations in leucine are
observed in liver without changes in valine or isoleucine (Green
et al., 2017), and cells from long-lived species have higher levels of
valine and leucine but not isoleucine (Ma et al., 2016).
Future research is required to test whether the elevations in
specific amino acids reflect a net increase in the breakdown of
protein and specific amino acids, and whether such effects occur
specifically in the liver. We observed no change in amino acid
abundance in quadriceps of males treated with 17aE2, indicating
that the response observed in the liver is unlikely to reflect an
influx of muscle metabolites into the liver, although it is possible
that 17aE2 effects on other tissues could be contributing to alter-
ations in liver metabolite profiles. Ultimately, metabolic flux analy-
sis is required to directly test whether the elevations of amino
acids represent a net increase in breakdown of existing protein
stores or whether alterations in the absorption/synthesis of these
compounds are responsible for the observed effects. It would be
of further interest to determine whether the observed elevations
in amino acids are also observable in unfasted animals, which
could suggest differences in basal utilization of different energy
substrates.
TABLE 3 Plasma free fatty acid responses to 17aE2. Significant changes are highlighted in bold.
Fatty acid
Effect (p-value) of 17aE2 treatment within each group Fold change with 17aE2 treatment
Male Female Cast male OVX female Male Female Cast male OVX female
22:6 0.0000 0.18 0.96 0.05 1.52 1.08 1.00 1.18
22:3 0.0002 0.01 0.06 0.44 2.26 1.35 1.49 1.11
22:2 0.0005 0.00 0.11 0.19 3.57 2.16 1.72 1.30
18:1 0.001 0.68 0.36 0.17 1.74 1.07 1.15 1.33
22:4 0.001 0.41 0.26 0.86 1.80 1.02 1.24 1.02
20:4 0.002 0.04 0.69 0.44 1.24 0.91 0.97 1.05
20:1 0.01 0.56 0.23 0.48 1.51 1.04 1.12 0.95
18:0 0.01 0.59 0.05 0.24 1.28 1.01 1.17 1.03
20:3 0.02 0.11 0.15 0.04 1.53 1.18 1.28 1.22
17:0 0.02 0.08 0.99 0.32 1.16 1.07 1.00 1.04
22:0 0.05 0.68 0.95 0.88 1.37 0.96 1.01 1.02
15:0 0.06 0.25 0.44 0.24 1.09 1.05 0.97 1.08
23:0 0.06 0.63 0.33 0.64 1.41 0.91 0.88 0.95
24:0 0.16 0.60 0.28 0.37 1.36 0.89 0.81 0.89
20:1 0.17 0.48 0.38 0.22 1.29 0.92 1.10 0.80
22:0 0.21 0.78 0.86 0.87 1.26 0.98 0.98 0.98
23:0 0.28 0.43 0.27 0.01 1.12 0.93 1.07 1.24
16:1 0.46 0.04 0.16 0.44 0.90 0.74 0.82 0.90
16:0 0.56 0.04 0.14 0.84 1.04 0.93 1.06 1.01
14:0 0.72 0.01 0.91 0.13 1.08 0.71 0.99 0.80
18:1 0.74 0.07 0.73 0.81 1.04 0.86 1.03 1.02
24:1 0.77 0.02 0.79 0.56 1.06 0.78 0.98 1.09
18:2 0.87 0.04 0.41 0.48 0.98 0.83 0.92 0.95
18:3 0.91 0.04 0.49 0.15 1.02 0.79 0.89 0.84
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The elevations in amino acids and urea cycle products with
17aE2 represent a male-specific phenotype, in that the response is
not observed in females. Such sex-specific effects on a metabolomic
scale are consistent with the sex-specific effects of 17aE2 on glu-
cose tolerance (Garratt et al., 2017) and hypothalamic inflammation
(Sadagurski, Cady & Miller, 2017). Furthermore, the response is not
observed in males castrated prior to treatment onset, suggesting that
this metabolic response to 17aE2 requires the presence of male
gonadal hormones. Castrated males show substantially fewer meta-
bolomic responses to 17aE2 in the liver than intact males, intact
females or females that were ovariectomised prior to treatment
onset. The male-specific effects of 17aE2 on free fatty acids in
plasma are also not observed in castrated males, indicating that the
role of male gonadal hormones in mediating responses to 17aE2 is
not restricted to the liver, but is also observed in other sites. Experi-
ments where castrated males are treated across life with 17aE2 are
now required to determine whether male gonadal hormones are
required to elicit the lifespan response to 17aE2. Understanding the
hormonal dependence of these responses to 17aE2 will be of impor-
tance in the potential translation of this drug, or related steroids, for
improving late-life health outcomes in humans of both sexes (Gonza-
lez-Freire, Diaz-Ruiz & de Cabo, 2017).
Future experiments are required to establish why the metabolic
effects of 17aE2 are dependent on the presence of male gonadal
hormones and the specific steroids that underlie sexually dimorphic
responses to 17aE2. The major hormone altered by male castration
is testosterone, and therefore, it is likely that the effectiveness of
17aE2 on mouse metabolism is dependent on circulating testos-
terone. While direct manipulation of testosterone levels over
extended periods of life in mice is technically unfeasible (due to the
pulsatile nature of its release and changes in concentration with
age), experiments where expression of the androgen receptor (AR) is
manipulated genetically may provide an insight into the role of
androgenic signaling in generating treatment responses to 17aE2,
and the role of androgenic signaling in aging more generally. The
apparent dependence of 17aE2 treatment responses on male gona-
dal hormones could occur if 17aE2 inhibits or protects against a
downstream action of testosterone, which ultimately constrains the
male-specific metabolomic response. As 17aE2 is a 5 alpha reductase
inhibitor (Schriefers et al., 1991), one such mechanism might involve
inhibition of testosterone’s conversion to dihydrotestosterone, which
is a more potent binder of the AR. This could inhibit specific effects
of testosterone on metabolism, which include protein anabolism and
inhibition of urea cycling (Lam et al., 2017; Rossetti, Steiner & Gor-
don, 2017), and contribute to the observed elevation of amino acids
and urea cycling. Under this hypothesis, inhibition AR expression in
mice would be expected to inhibit 17aE2 responses, and other 5-
alpha reductase inhibitors might induce similar effects to 17aE2.
Another related hypothesis is that the activity, metabolism and/or
signaling effects of 17aE2 are dependent on testosterone, and without
the presence of testosterone the biological effects of 17aE2 are
weaker. Two of the liver metabolites that showed strong, sex-specific
responses to 17aE2 were the estrogenic compounds estriol-3-sulfate
and 16-oxoestradiol 3-sulfate—products that can be generated from
metabolism of estradiol. Estriol is produced from the placenta during
pregnancy in females and during nonpregnant states is generated from
estradiol or estrone via 16-alpha hydroxylation (Longcope 1984). Most
estriol in circulation is conjugated, of which estriol-3-sulfate is the
most abundant form (Tanaka et al. 1984). 16-oxoestradiol is an inter-
mediate metabolite in the conversion of estradiol to estriol (Pasqualini
& Kincl 1985). Considering that many of the xenobiotic enzymes that
metabolize steroids show sexual dimorphism in expression (Waxman
& Holloway, 2009), it is possible that 17aE2 may be metabolized into a
different form, in either males or females, which could influence either
the transport of this steroid, its activation/inactivation, or its ability to
bind to estrogen receptors. 17aE2 is readily conjugated into various
forms in humans (Hobe et al. 2002), and understanding the metabo-
lism of this steroid may be important when considering translational
potential of this drug to humans.
The longevity benefits of 17aE2 highlight the potentially impor-
tant role of steroids in control of mammalian lifespan, and a greater
understanding of changes in steroidogenic signaling that occur with
life extension could provide an insight into pathways and molecules
that control aging in one or both sexes. In relation to circulating
estrogens, much previous research focus has been placed on the role
of 17-b estradiol in controlling metabolism and generating sex differ-
ences in health and metabolic dysfunction at different periods of life.
However, the role of 17aE2 in slowing mouse aging, improving
mouse metabolism, and generating metabolomic responses associ-
ated with life-extension points to an important role of additional
estrogens in controlling mammalian health and aging. 17aE2 has a
weaker binding affinity to classical estrogen receptors than 17-b
estradiol (Anstead, Carlson & Katzenellenbogen, 1997), although
experiments with estrogen receptor knockout mice are required to
fully establish whether 17aE2 acts independently or through these
receptors to induce its metabolic and anti-aging effects. Recent
research suggests the metabolic benefits of 17-b estradiol on mouse
weight and body composition can also be at least partly recapitu-
lated by treatment with chemically altered, pathway preferential
estrogens (PaPEs). The structural modifications of PaPEs cause these
molecules to have a weaker binding affinity to estrogen receptors,
and so do not cause feminization, but are still able to activate the
extranuclear-initiated ER signaling pathway and activate metabolic
processes sufficient to influence fat deposition (Madak-Erdogan
et al., 2016). Future experiments with PaPEs and more diverse estro-
gens like estriol (which was observed to be strongly elevated by
17aE2 treatment) could provide a greater insight into the role of dif-
ferent aspects of estrogenic signaling in metabolism and aging, and
might ultimately lead to interventions that can be applied to protect
against age-related disease and metabolic dysfunction in humans.
4 | EXPERIMENTAL PROCEDURES
UM-HET3 mice were produced as previously described (Miller et al.,
2014; Strong et al., 2008). The mothers of the test mice were
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CByB6F1/J, JAX stock #100009, whose female parents are BALB/
cByJ and whose male parents are C57BL/6J. The fathers of the test
mice were C3D2F1/J, JAX stock #100004, whose mothers are C3H/
HeJ, and whose fathers are DBA/2J. Mice in breeding cages
received Purina 5008 mouse chow, and weaned animals were fed
Purina 5LG6.
Mice were housed as previously described (Miller et al., 2014;
Strong et al., 2008) in plastic cages with metal tops, using ¼-inch
corn-cob bedding (Bed O’Cobs, produced by The Andersons, PO
Box 114, Maumee, OH, USA). Mice were given free access to water,
using water bottles rather than an automated watering system. Mice
were housed in ventilated cages and were transferred to fresh cages
every 14 days. Temperature was maintained within the range of 21–
23°C.
4.1 | Surgical procedures
At three months of age, all animals went through castration, ovariec-
tomy, or a sham procedure. All animals were anaesthetized by injec-
tion of 250 mg/kg tribromoethanol, and given a single preoperative
injection of the analgesia carprofen, at 5 mg/kg.
4.2 | Castration and sham castration
After surgical preparation, an incision was made in the caudal end of
each scrotal sac, the testicle was pulled through the incision by gen-
tle traction, and the blood vessels, vas deferens, and deferential ves-
sels were clamped and sutured. The incision was closed with tissue
adhesive. For sham surgery, the testicles were exteriorized and then
replaced in the scrotum, without being ligated or excised.
4.3 | Ovariectomy or sham ovariectomy
After surgical preparation, an incision was made on the left side per-
pendicular to the vertebral column approximately midway between
the iliac crest and the last rib. The ovarian fat pad was grasped and
exteriorized. The pedicle under the ovarian blood vessels and fat pad
under the ovary were grasped and crushed, the pedicle cut on the
ovary side and the ovary removed, and the blood vessels tied with
absorbable suture. The abdominal wall was closed with absorbable
suture, and skin was closed with staples. The procedure was then
repeated on the opposite side. For sham ovariectomy, animals
underwent the same surgical procedure, but the ovary and fat pad
were exteriorized and replaced without being excised.
4.4 | Diets
At four months of age, animals in different sibling groups were ran-
domly allocated to control or 17aE2 treatment. Animals in the con-
trol group remained on the 5LG6 diet, while animals allocated to
17aE2 had their diet switched to a food containing this drug.
Diets were prepared by TestDiet, Inc., a division of Purina Mills
(Richmond, IN, USA). Purina 5LG6 food contained 17aE2 and was
also used as the control diet. 17aE2 was purchased from Steraloids
Inc. (Newport, RI, USA) and mixed at a dose of 14.4 milligrams per
kilogram diet (14.4 ppm). These methods followed those used by the
NIA Interventions Testing Program.
4.5 | Metabolomics analysis
Livers, muscle, and plasma were harvested during the morning, from
12-month-old mice after 18 hr of fasting. Samples were frozen with
liquid nitrogen and stored at 70°C. Tissues were ground under liq-
uid nitrogen prior to metabolomics analysis. See Supplementary
methods for muscle metabolomic analysis protocol.
4.6 | Sample preparation
Mouse liver samples were analyzed by liquid chromatography–mass
spectrometry (LC-MS). Snap-frozen and pulverized liver samples
were resuspended in cold 80:20 methanol:water at 40 lg/ll. Sam-
ples were subjected to three freeze–thaw cycles, with alternating
37°C and 80°C liquid baths in 30-s intervals to ensure complete
cell lysis, vortexing, and a 2-min sonication. Samples were thereafter
placed in the 20°C freezer for 30 min to allow for precipitation of
protein, vortexed for 60 s, and centrifuged at 14,000 g 9 10 min at
4°C. Supernatants were collected and transferred to LC-MS vials.
For measurement of small lipids, identical preparation protocols were
used with the exception of 80:20 ethanol:water for extraction sol-
vent, followed by solid-phase extraction of lipid metabolites using a
Strata-X polymeric 10 mg/ml 96-well SPE plate, as previously
described (Watrous et al., 2017).
4.7 | LC-MS-based metabolomics
LC-MS/MS-based metabolomics analysis was performed using a
Thermo QExactive orbitrap mass spectrometer coupled to a Thermo
Vanquish UPLC system. For analysis of polar molecules, we achieved
chromatographic separation using a Millipore (Sequant) Zic-pHILIC
2.1 9 150 mm 5um column maintained at 25°C. Compounds were
eluted via a 19-min linear gradient starting from 90:10 acetoni-
trile:20 mM ammonium bicarbonate to 45:55 acetonitrile:20 mM
ammonium bicarbonate. For chromatographic separation of bioactive
lipids, we used a Phenomenex Kinetex C18 (1.7 lm particle size,
100 9 2.1 mm) column maintained at 50⁰C using mobile phases A
(70% water, 30% acetonitrile and 0.1% acetic acid) and B (50% ace-
tonitrile, 50% isopropanol, 0.02% acetic acid) running the following
gradient: 1% B from 1.00 to 0.25 min, 1% to 55% B from 0.25 to
5.00 min, 55% to 99% B from 5.00 to 5.50 min, and 99% B from
5.50 to 7.00 min. For the analysis of nonpolar lipids, we used the
same column and column temperature as for the bioactive lipids
analysis, but separation in positive ion mode was achieved using
mobile phases A (Water with 0.1% formic acid and 10 mM ammo-
nium formate) and B (50% acetonitrile, 50% isopropanol, and 0.1%
formic acid) running at 5% B from 2.00 to 0.25 min, 5% to 50% B
from 0.25 to 2.00 min, 50% to 99% B from 5.00 to 9.50 min, and
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99% B from 9.50 to 13.00 min. For separation in negative ion mode
mobile phase A (1 mM ammonium fluoride) and B (50% acetonitrile,
50% isopropanol, and 1 mM ammonium fluoride) were run with the
same gradient as just described. For all methods, a Thermo QExac-
tive orbitrap mass spectrometer was operated in positive and nega-
tive ion modes for nonpolar lipids and polar molecules and negative
mode only for bioactive lipid analysis.
4.8 | Chemical networking and metabolite
identification
Collected data were imported into the mzMine 2.26 software suite
for analysis. Pure standards were used for identification of metabo-
lites through manual inspection of spectral peaks and matching of
retention time and MS1 accurate mass, with confirmation of identifi-
cation through comparison to MS/MS fragmentation patterns. For
unknown metabolites, chemical networking was performed by Global
Natural Products Social molecular networking (GNPS, http://gnps.uc
sd.edu) and all visualization was performed in Cytoscape (Watrous
et al., 2012). The data were clustered with a parent mass tolerance
of 1.0 Da and a MS/MS fragment ion tolerance of 0.15 Da. The
spectra in the network were searched against GNPS spectral
libraries, and all connections were required to a minimum cosine
score of 0.7 and at least 3 matched peaks. Estriol 3-sulfate and 16-
oxoestradiol 3-sulfate were identified through manual inspection of
spectral peaks with confirmation of identification through compar-
ison to MS/MS fragmentation patterns.
4.9 | Statistical analysis
4.9.1 | Analysis of untargeted metabolites
We first focused on metabolite responses that occur in mice where
gonadal hormone production was unaltered, that is, mice that had
only been through sham surgery, as data on lifespan responses to
17aE2 were conducted in male and female mice without surgical
manipulation (Strong et al., 2016).
For each metabolite, we fitted a two-way ANOVA model testing
the effects of sex, treatment, and the interaction between sex and
treatment with data from sham-operated males and females. The
interaction term in the model was our primary interest as it indicates
that the effect of 17aE2 treatment was modified by sex. By scanning
through all interactions, we were able to identify metabolites that
reveal significant treatment by sex interaction. Because multiple
two-way interaction effects were tested across the dataset, we
adjusted raw p-values with False Discovery Rate (FDR) method (Ben-
jamini & Hochberg, 1995).
For those metabolites that showed a significant sex by treatment
interaction, we subsequently tested whether male castration or
female ovariectomy influenced the treatment response within either
sex. In this analysis, data were split according to sex, then tested for
an effect of surgery (e.g., within males, castration or sham castration;
within females, ovariectomy or sham ovariectomy), treatment, and
an interaction between surgery and treatment. An interaction
between surgery and treatment indicates that the response to
17aE2 depends on whether animals had been gonadectomized (and
gonadal hormones are removed) or not.
4.9.2 | Analysis of known metabolites
For analysis of metabolites that were identified against a standard
reference library, we conducted Quantitative Metabolomic Set
Enrichment Analysis using Metaboanalyst 3.0 (Xia & Wishart, 2010)
after matching metabolites to their respective HMDB IDs. Data for
control and 17aE2 animals within each sex and surgery group were
uploaded to the metaboanalyst 3.0 website separately. We con-
ducted quantitative enrichment analysis by uploading a concentra-
tion table that showed abundance values for each metabolite for
each individual, with animals differentiated according to whether
they were control or 17aE2. Data were log-transformed, and then,
enrichment analysis was conducted against the “pathway-associated
metabolite sets” library. Enrichment for a specific pathway was con-
sidered statistically significant when the FDR p-value was lower than
0.05.
We also looked within the known metabolite data to test
whether there were changes in individual metabolites that differed
depending on sex, and whether sex-specific responses in these
instances were altered by surgical removal of gonads in either males
or females. These statistical tests were conducted as part of the lar-
ger analysis of untargeted metabolite responses, but we present sex
by treatment interaction responses that are uncorrected for FDR.
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